Atea Pharmaceuticals director proposes 22,619-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atea Pharmaceuticals, Inc. director Bruno Lucidi reported a proposed sale of 22,619 common shares, with an aggregate market value of $89,219.37 and an approximate sale date of November 19, 2026. The notice names Morgan Stanley Smith Barney LLC as broker. Lucidi acquired the shares on November 19, 2026, through a stock option exercise from the issuer, with cash payment. It also reports a sale of 6,741 common shares on November 17, 2026, for gross proceeds of $27,189.82.
Key Figures
Key Terms
Stock Option Exercise financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.